Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 15-20

  Barch, Deanna M ^a,b   Bustillo, Juan ^c   Gaebel, Wolfgang ^d   Gur, Raquel ^e,f   Heckers, Stephan ^g   Malaspina, Dolores ^h,i   Owen, Michael J ^j   Schultz, Susan ^k   Tandon, Rajiv ^l   Tsuang, Ming ^m,n,o,p   Van Os, Jim ^q,r   Carpenter, William ^s  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d Department of Orthopedic Surgery   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h NEW YORK UNIVERSITY   (United States)

ⁱ Creedmoor Psychiatric Center   (United States)

^j CARDIFF UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF IOWA   (United States)

^l UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^p HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r KING'S COLLEGE LONDON   (United Kingdom)

^s MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

more..

Author keywords

Cognition; Diagnosis; Dimensions; DSM 5; Psychosis; Schizoaffective

Indexed keywords

ANAMNESIS; ANHEDONIA; ANTISOCIAL BEHAVIOR; AVOLITION; BEHAVIOR; BIPOLAR DISORDER; BLUNTED AFFECT; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COGNITIVE DEFECT; COMORBIDITY; CONCEPTUAL FRAMEWORK; DELUSION; DEMENTIA; DEPRESSION; DIAGNOSTIC VALUE; DIMENSIONAL ASSESSMENT; DISEASE SEVERITY; DSM-5; EMOTIONAL DISORDER; EMOTIONALITY; EVIDENCE BASED MEDICINE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; GENETIC VARIABILITY; HALLUCINATION; HUMAN; MANIA; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; NOTE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESTRICTED EMOTIONAL EXPRESSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT; SENSITIVITY AND SPECIFICITY; SPEECH DISORDER; SYMPTOM ASSESSMENT;

COGNITION; DIAGNOSIS; DIMENSIONS; DSM-5; PSYCHOSIS; SCHIZOAFFECTIVE;

BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HALLUCINATIONS; HUMANS; LOGIC; PSYCHOTIC DISORDERS;

EID: 84884147000     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.04.027     Document Type: Note

References (83)

1. Addington J., Mancuso E. Cognitive-behavioral therapy for individuals at high risk of developing psychosis. J. Clin. Psychol. 2009, 65(8):879-890.
2. Addington D., Addington J., Patten S. Depression in people with first-episode schizophrenia. Br. J. Psychiatry Suppl. 1998, 172(33):90-92.
3. Barch D.M., Carter C.S., Cohen J.D. Context processing deficit in schizophrenia: diagnostic specificity, 4-week course, and relationships to clinical symptoms. J. Abnorm. Psychol. 2003, 112(132-143):132-143.
4. Barch D.M., Mitropoulou V., Harvey P.D., New A.S., Silverman J.M., Siever L.J. Context-processing deficits in schizotypal personality disorder. J. Abnorm. Psychol. 2004, 113(4):556-568.
5. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 2006, 163(3):418-425.
6. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., Harvey P.D. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 2008, 63(5):505-511.
7. Bralet M.C., Falissard B., Neveu X., Lucas-Ross M., Eskenazi A.M., Keefe R.S. Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. Eur. Psychiatry 2007, 22(6):365-370.
8. Cervellione K.L., Burdick K.E., Cottone J.G., Rhinewine J.P., Kumra S. Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome. J. Am.Acad. Child and Adolesc. Psychiatry 2007, 46(7):867-878.
9. Chia M.Y., Chan W.Y., Chua K.Y., Lee H., Lee J., Lee R., Lim C., Tay E., Woon P.S., Keefe R.S., Sim K. The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Res. 2010, 178:33-38.
10. Crumlish N., Whitty P., Kamali M., Clarke M., Browne S., McTigue O., Lane A., Kinsella A., Larkin C., O'Callaghan E. Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr. Scand. 2005, 112(6):449-455.
11. Czobor P., Jaeger J., Berns S.M., Gonzalez C., Loftus S. Neuropsychological symptom dimensions in bipolar disorder and schizophrenia. Bipolar Disord. 2007, 9(1-2):71-92.
12. Delawalla Z., Barch D.M., Fisher Eastep J.L., Thomason E.S., Hanewinkel M.J., Thompson P.A., Csernansky J.G. Factors mediating cognitive deficits and psychopathology among siblings of individuals with schizophrenia. Schizophr. Bull. 2006, 32:525-537.
13. Depp C.A., Moore D.J., Sitzer D., Palmer B.W., Eyler L.T., Roesch S., Lebowitz B.D., Jeste D.V. Neurocognitive impairment in middle-aged and older adults with bipolar disorder: comparison to schizophrenia and normal comparison subjects. J. Affect. Disord. 2007, 101(1-3):201-209.
14. Dichter G.S., Bellion C., Casp M., Belger A. Impaired modulation of attention and emotion in schizophrenia. Schizophr. Bull. 2010, 36:595-606.
15. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry 2007, 64(5):532-542.
16. Dickinson D., Ragland J.D., Gold J.M., Gur R.C. General and specific cognitive deficits in schizophrenia: Goliath defeats David?. Biol. Psychiatry 2008, 64(9):823-827.
17. Dowd E., Barch D.M. Subjective emotional experience in schizophrenia: neural and behavioral markers. Biol. Psychiatry 2010, 67(10):902-911.
18. Emsley R.A., Niehaus D.J., Mbanga N.I., Oosthuizen P.P., Stein D.J., Maritz J.S., Pimstone S.N., Hayden M.R., Laurent C., Deleuze J.F., Mallet J. The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia. Schizophr. Res. 2001, 47(2-3):149-157.
19. Fahim C., Stip E., Mancini-Marie A., Mensour B., Boulay L.J., Leroux J.M., Beaudoin G., Bourgouin P., Beauregard M. Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res. 2005, 140(1):1-15.
20. Gleeson J.F., Cotton S.M., Alvarez-Jimenez M., Wade D., Gee D., Crisp K., Pearce T., Newman B., Spiliotacopoulos D., Castle D., McGorry P.D. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J. Clin. Psychiatry 2009, 70(4):477-486.
21. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am. J. Psychiatry 1999, 156(12):1944-1950.
22. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
23. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72(1):41-51.
24. Green M.F., Nuechterlein K.H., Kern R.S., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S., Mesholam-Gately R., Seidman L.J., Stover E., Marder S.R. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. Am. J. Psychiatry 2008, 165:221-228.
25. Gruber S.A., Rosso I.M., Yurgelun-Todd D. Neuropsychological performance predicts clinical recovery in bipolar patients. J. Affect. Disord. 2008, 105(1-3):253-260.
26. Gur R.E., Kohler C.G., Ragland J.D., Siegel S.J., Lesko K., Bilker W.B., Gur R.C. Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr. Bull. 2006, 32(2):279-287.
27. Gur R.E., Loughead J., Kohler C.G., Elliott M.A., Lesko K., Ruparel K., Wolf D.H., Bilker W.B., Gur R.C. Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch. Gen. Psychiatry 2007, 64(12):1356-1366.
28. Harvey P.D., Keefe R.S., Patterson T.L., Heaton R.K., Bowie C.R. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. J. Clin. Exp. Neuropsychol. 2009, 31(4):462-471.
29. Heinrichs R.W., Ammari N., McDermid Vaz S., Miles A.A. Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?. Schizophr. Res. 2008, 99(1-3):149-154.
30. Heinrichs R.W., Goldberg J.O., Miles A.A., McDermid Vaz S. Predictors of medication competence in schizophrenia patients. Psychiatry Res. 2008, 157(1-3):47-52.
31. Henry J.D., Green M.J., de Lucia A., Restuccia C., McDonald S., O'Donnell M. Emotion dysregulation in schizophrenia: reduced amplification of emotional expression is associated with emotional blunting. Schizophr. Res. 2007, 95(1-3):197-204.
32. Hill S.K., Keshavan M.S., Thase M.E., Sweeney J.A. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am. J. Psychiatry 2004, 161(6):996-1003.
33. Hill S.K., Schuepbach D., Herbener E.S., Keshavan M.S., Sweeney J.A. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr. Res. 2004, 68(1):49-63.
34. Hill S.K., Sweeney J.A., Hamer R.M., Keefe R.S., Perkins D.O., Gu H., McEvoy J.P., Lieberman J.A. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J. Int. Neuropsychol. Soc. 2008, 14(2):209-221.
35. Hurford I.M., Marder S.R., Keefe R.S., Reise S.P., Bilder R.M. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr. Bull. 2011, 37:538-545.
36. Jaeger J., Berns S., Loftus S., Gonzalez C., Czobor P. Neurocognitive test performance predicts functional recovery from acute exacerbation leading to hospitalization in bipolar disorder. Bipolar Disord. 2007, 9(1-2):93-102.
37. Kaneda Y., Sumiyoshi T., Keefe R., Ishimoto Y., Numata S., Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin. Neurosci. 2007, 61(6):602-609.
38. Keefe R.S., Harvey P.D., Lenzenweger M.F., Davidson M., Apter S.H., Schmeidler J., Mohs R.C., Davis K.L. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 1992, 44(2):153-165.
39. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68(2-3):283-297.
40. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64(6):633-647.
41. Keefe R.S., Harvey P.D., Goldberg T.E., Gold J.M., Walker T.M., Kennel C., Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr. Res. 2008, 102(1-3):108-115.
42. Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am. J. Psychiatry 1999, 156(3):406-411.
43. Kerns J.B., Berenbaum H. Cognitive impairments associated with formal thought disorder in people with schizophrenia. J. Abnorm. Psychol. 2002, 111(2):211-224.
44. Kimhy D., Yale S., Goetz R.R., McFarr L.M., Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr. Bull. 2006, 32(2):274-278.
45. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
46. Krabbendam L., Arts B., van Os J., Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr. Res. 2005, 80(2-3):137-149.
47. Kraepelin E. Dementia Praecox and Paraphrenia 1971, Livingston, Edinburgh, (Original work published 1919).
48. Malaspina D., Coleman E. Olfaction and social drive in schizophrenia. Arch. Gen. Psychiatry 2003, 60(6):578-584.
49. Malhi G.S., Green M., Fagiolini A., Peselow E.D., Kumari V. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord. 2008, 10:215-230.
50. Malla A.K., Takhar J.J., Norman R.M., Manchanda R., Cortese L., Haricharan R., Verdi M., Ahmed R. Negative symptoms in first episode non-affective psychosis. Acta Psychiatr. Scand. 2002, 105(6):431-439.
51. Marder S.R. Drug initiatives to improve cognitive function. J. Clin. Neuropsychiatry 2006, 67(Suppl. 9):31-35. (discussion 36-42).
52. Marder S.R., Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res. 2004, 72(1):5-9.
53. Martinez-Aran A., Vieta E., Reinares M., Colom F., Torrent C., Sanchez-Moreno J., Benabarre A., Goikolea J.M., Comes M., Salamero M. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am. J. Psychiatry 2004, 161(2):262-270.
54. McClure M.M., Bowie C.R., Patterson T.L., Heaton R.K., Weaver C., Anderson H., Harvey P.D. Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships?. Schizophr. Res. 2007, 89(1-3):330-338.
55. Minas I.H., Klimidis S., Stuart G.W., Copolov D.L., Singh B.S. Positive and negative symptoms in the psychoses: principal components analysis of items from the scale for the assessment of positive symptoms and the scale for the assessment of negative symptoms. Compr. Psychiatry 1994, 35:135-144.
56. Mueser K.T., Sayers S.L., Schooler N.R., Mance R.M., Haas G.L. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms. Am. J. Psychiatry 1994, 151(10):1453-1462.
57. Nakaya M., Ohmori K. A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res. 2008, 158(2):256-259.
58. Olvet D.M., Stearns W.H., McLaughlin D., Auther A.M., Correll C.U., Cornblatt B.A. Comparing clinical and neurocognitive features of the schizophrenia prodrome to the bipolar prodrome. Schizophr. Res. 2010, 123(1):59-63.
59. Owen M.J., Craddock N., Jablensky A. The genetic deconstruction of psychosis. Schizophr. Bull. 2007, 33(4):905-911.
60. Peralta V., Cuesta M.J. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. Schizophr. Res. 1999, 38:13-26.
61. Peralta V., Cuesta M.J. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr. Res. 2001, 49(3):269-285.
62. Peralta V., Cuesta M.J. Exploring the borders of the schizoaffective spectrum: a categorical and dimensional approach. J. Affect. Disord. 2009, 108:71-86.
63. Perlstein W.M., Dixit N.K., Carter C.S., Noll D.C., Cohen J.D. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol. Psychiatry 2003, 53:25-38.
64. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., Bromet E. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2009, 35:1022-1029.
65. Rodriguez-Sanchez J.M., Perez-Iglesias R., Gonzalez-Blanch C., Pelayo-Teran J.M., Mata I., Martinez O., Sanchez-Cubillo I., Vazquez-Barquero J.L., Crespo-Facorro B. 1-year follow-up study of cognitive function in first-episode non-affective psychosis. Schizophr. Res. 2008, 104(1-3):165-174.
66. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr. Bull. 1998, 24(3):425-435.
67. Sayers S.L., Curran P.J., Mueser K.T. Factor structure and construct validity of the scale for the assessment of negative symptoms. Psychol. Assess. 1996, 8:269-280.
68. Schretlen D.J., Cascella N.G., Meyer S.M., Kingery L.R., Testa S.M., Munro C.A., Pulver A.E., Rivkin P., Rao V.A., Diaz-Asper C.M., Dickerson F.B., Yolken R.H., Pearlson G.D. Neuropsychological functioning in bipolar disorder and schizophrenia. Biol. Psychiatry 2007, 62(2):179-186.
69. Smith M.J., Barch D.M., Csernansky J.G. Bridging the gap between schizophrenia and psychotic mood disorders: relating neurocognitive deficits to psychopathology. Schizophr. Res. 2009, 107(1):69-75.
70. Strauss J.S., Carpenter W.T., Bartko J.J. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr. Bull. 1974, (11):61-69.
71. Strauss M.E., Buchanan R.W., Hale J. Relations between attentional deficits and clinical symptoms in schizophrenic outpatients. Psychiatry Res. 1993, 47:205-213.
72. Strauss G.P., Horan W.P., Miski P., Fisher B.A., Kirkpatrick B., Buchanan R.W., Green M., Carpenter W.T. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished emotional expression clusters predict clinical presentation and functional outcome. J. Psychiatr. Res. 2013, 47:783-790.
73. Suslow T., Junghanns K., Weitzsch C., Arolt V. Relations between neuropsychological vulnerability markers and negative symptoms in schizophrenia. Psychopathology 1998, 31(4):178-187.
74. Tabares-Seisdedos R., Balanza-Martinez V., Sanchez-Moreno J., Martinez-Aran A., Salazar-Fraile J., Selva-Vera G., Rubio C., Mata I., Gomez-Beneyto M., Vieta E. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J. Affect. Disord. 2008, 109(3):286-299.
75. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110(1-3):1-23.
76. Tattan T.M., Creed F.H. Negative symptoms of schizophrenia and compliance with medication. Schizophr. Bull. 2001, 27(1):149-155.
77. Toomey R., Kremen W.S., Simpson J.C., Samson J.A., Seidman L.J., Lyons M.J., Faraone S.V., Tsuang M.T. Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Am. J. Psychiatry 1997, 154(3):371-377.
78. Tremeau F., Goggin M., Antonius D., Czobor P., Hill V., Citrome L. A new rating scale for negative symptoms: the Motor-Affective-Social Scale. Psychiatry Res. 2008, 160(3):346-355.
79. Velligan D.I. Cognitive behavior therapy for psychosis: where have we been and where are we going?. Schizophr. Bull. 2009, 35(5):857-858.
80. Velligan D.I., DiCocco M., Bow-Thomas C.C., Cadle C., Glahn D.C., Miller A.L., Biggs M.M., Shores-Wilson K., McKenzie C.A., Crismon M.L. A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr. Res. 2004, 71(2-3):273-283.
81. Ventura J., Reise S.P., Keefe R.S., Baade L.E., Gold J.M., Green M.F., Kern R.S., Mesholam-Gately R., Nuechterlein K.H., Seidman L.J., Bilder R.M. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr. Res. 2010, 121:24-31.
82. Waltz J.A., Schweitzer J.B., Gold J.M., Kurup P.K., Ross T.J., Salmeron B.J., Rose E.J., McClure S.M., Stein E.A. Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology 2009, 34(6):1567-1577.
83. Wilk C.M., Gold J.M., Humber K., Dickerson F., Fenton W.S., Buchanan R.W. Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr. Res. 2004, 70(2-3):175-186.